Chandna Arjun, Koshiaris Constantinos, Mahajan Raman, Ahmad Riris Adono, Van Anh Dinh Thi, Choudhury Khalid Shams, Keang Suy, Nguyen Phung Nguyen The, Rattanavong Sayaphet, Vannachone Souphaphone, Yosia Mikhael, Waithira Naomi, Abdad Mohammad Yazid, Thaipadungpanit Janjira, Turner Paul, Phuc Phan Huu, Mondal Dinesh, Mayxay Mayfong, Liem Bui Thanh, Ashley Elizabeth A, Arguni Eggi, Perera-Salazar Rafael, Richard-Greenblatt Melissa, Lubell Yoel, Burza Sakib
Cambodia Oxford Medical Research Unit, Angkor Hospital for Children, Siem Reap, Cambodia; Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.
Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus.
Lancet Child Adolesc Health. 2025 Sep;9(9):634-645. doi: 10.1016/S2352-4642(25)00183-X.
Prognostic tools for febrile illnesses are urgently required in resource-constrained community contexts. Circulating immune and endothelial activation markers stratify risk in common childhood infections. We aimed to assess their use in children with febrile illness presenting from rural communities across Asia.
Spot Sepsis was a prospective cohort study across seven hospitals in Bangladesh, Cambodia, Indonesia, Laos, and Viet Nam that serve as a first point of contact with the formal health-care system for rural populations. Children were eligible if aged 1-59 months and presenting with a community-acquired acute febrile illness that had lasted no more than 14 days. Clinical parameters were recorded and biomarker concentrations measured at presentation. The primary outcome measure was severe febrile illness (death or receipt of organ support) within 2 days of enrolment. Weighted area under the receiver operating characteristic curves (AUC) were used to compare prognostic accuracy of endothelial activation markers (ANG-1, ANG-2, and soluble FLT-1), immune activation markers (CHI3L1, CRP, IP-10, IL-1ra, IL-6, IL-8, IL-10, PCT, soluble TNF-R1, soluble TREM1 [sTREM1], and soluble uPAR), WHO danger signs, the Liverpool quick Sequential Organ Failure Assessment (LqSOFA) score, and the systemic inflammatory response syndrome (SIRS) score. Prognostic accuracy of combining WHO danger signs and the best performing biomarker was analysed in a weighted logistic regression model. Weighted measures of classification were used to compare prognostic accuracies of WHO danger signs and the best performing biomarker and to determine the number of children needed to test (NNT) to identify one additional child who would progress to severe febrile illness. The study was prospectively registered on ClinicalTrials.gov, NCT04285021.
3423 participants were recruited between March 5, 2020, and Nov 4, 2022, 18 (0·5%) of whom were lost to follow-up. 133 (3·9%) of 3405 participants developed severe febrile illness (22 deaths, 111 received organ support; weighted prevalence 0·34% [95% CI 0·28-0·41]). sTREM1 showed the highest prognostic accuracy to identify patients who would progress to severe febrile illness (AUC 0·86 [95% CI 0·82-0·90]), outperforming WHO danger signs (0·75 [0·71-0·80]; p<0·0001), LqSOFA (0·74 [0·69-0·78]; p<0·0001), and SIRS (0·63 [0·58-0·68]; p<0·0001). Combining WHO danger signs with sTREM1 (0·88 [95% CI 0·85-0·91]) did not improve accuracy in identifying progression to severe febrile illness over sTREM1 alone (p=0·24). Sensitivity for identifying progression to severe febrile illness was greater for sTREM1 (0·80 [95% CI 0·73-0·85]) than for WHO danger signs (0·72 [0·66-0·79]; NNT=3000), whereas specificities were comparable (0·81 [0·78-0·83] for sTREM1 vs 0·79 [0·76-0·82] for WHO danger signs). Discrimination of immune and endothelial activation markers was best for children who progressed to meet the outcome more than 48 h after enrolment (sTREM1: AUC 0·94 [95% CI 0·89-0·98]).
sTREM1 showed the best prognostic accuracy to discriminate children who would progress to severe febrile illness. In resource-constrained community settings, an sTREM1-based triage strategy might enhance early recognition of risk of poor outcomes in children presenting with febrile illness.
Médecins Sans Frontières, Spain, and Wellcome.
For the Arabic and French translations of the abstract see Supplementary Materials section.
在资源有限的社区环境中,迫切需要针对发热性疾病的预后评估工具。循环免疫和内皮激活标志物可对常见儿童感染的风险进行分层。我们旨在评估其在亚洲农村社区发热性疾病患儿中的应用。
“Spot Sepsis”是一项在孟加拉国、柬埔寨、印度尼西亚、老挝和越南的七家医院开展的前瞻性队列研究,这些医院是农村人口与正规医疗系统的首个接触点。年龄在1至59个月之间、患有社区获得性急性发热性疾病且病程不超过14天的儿童符合入选标准。记录临床参数,并在就诊时测量生物标志物浓度。主要结局指标是入组后2天内出现的严重发热性疾病(死亡或接受器官支持)。采用受试者工作特征曲线下面积(AUC)的加权值来比较内皮激活标志物(ANG-1、ANG-2和可溶性FLT-1)、免疫激活标志物(CHI3L1、CRP、IP-10、IL-1ra、IL-6、IL-8、IL-10、PCT、可溶性TNF-R1、可溶性TREM1 [sTREM1]和可溶性uPAR)、世界卫生组织(WHO)危险体征、利物浦快速序贯器官衰竭评估(LqSOFA)评分以及全身炎症反应综合征(SIRS)评分的预后准确性。在加权逻辑回归模型中分析将WHO危险体征与表现最佳的生物标志物相结合的预后准确性。使用分类的加权指标来比较WHO危险体征与表现最佳的生物标志物的预后准确性,并确定为识别一名进展为严重发热性疾病的额外儿童所需检测的儿童数量(NNT)。该研究已在ClinicalTrials.gov上进行前瞻性注册,注册号为NCT04285021。
2020年3月5日至2022年11月4日期间招募了3423名参与者,其中18名(0.5%)失访。3405名参与者中有133名(3.9%)发生了严重发热性疾病(22例死亡,111例接受器官支持;加权患病率0.34% [95%CI 0.28 - 0.41])。sTREM1在识别将进展为严重发热性疾病的患者方面显示出最高的预后准确性(AUC 0.86 [95%CI 0.82 - 0.90]),优于WHO危险体征(0.75 [0.71 - 0.80];p<0.0001)、LqSOFA(0.74 [0.69 - 0.78];p<0.0001)和SIRS(0.63 [0.58 - 0.68];p<0.0001)。将WHO危险体征与sTREM1相结合(0.88 [95%CI 0.85 - 0.91])在识别进展为严重发热性疾病方面的准确性并不优于单独使用sTREM1(p = 0.24)。sTREM1识别进展为严重发热性疾病的敏感性(0.80 [95%CI 0.73 - 0.85])高于WHO危险体征(0.72 [0.66 - 0.79];NNT = 3000),而特异性相当(sTREM1为0.81 [0.78 - 0.83],WHO危险体征为匹配0.79 [0.76 - 0.82])。免疫和内皮激活标志物对入组后超过48小时进展为达到结局的儿童的区分效果最佳(sTREM1:AUC 0.94 [95%CI 0.89 - 0.98])。
sTREM1在区分将进展为严重发热性疾病的儿童方面显示出最佳的预后准确性。在资源有限的社区环境中,基于sTREM1的分诊策略可能会提高对发热性疾病患儿不良结局风险的早期识别。
无国界医生组织、西班牙和惠康基金会。
摘要的阿拉伯语和法语翻译见补充材料部分。